Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Coprescription of antiulcer drugs with SSRIs is fairly common
| The first 150 words of the full text of this article appear below. |
EDITOR
The paper by de Abajo et al raises the possibility of an
increased risk of upper gastrointestinal bleeding associated with
selective serotonin reuptake inhibitors.1 The authors excluded patients with cancer, oesophageal varices, Mallory-Weiss disease, alcoholism, liver disease, and coagulopathies, but it is
not clear if they excluded patients who were coprescribed antiulcer treatments. They do mention antecedents of upper gastrointestinal disorders as potential cofounders that were adjusted for.
To investigate this issue further we examined a large prescription
database provided by the general medical services in the Republic of
Ireland. For November 1998 we determined the odds ratios to estimate
the relative risk for the coprescription of antiulcer drugs
(including H2 antagonists, proton pump inhibitors, and
prostaglandin analogues but excluding antacids) with selective serotonin reuptake inhibitors and other antidepressants (table). We
excluded people who were coprescribed aspirin, non-steroidal anti-inflammatory agents, or corticosteroids as this may have been
cytoprotective coprescribing.